Compare Revvity Inc (RVTY) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Target Corporation — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Target Corporation trades at $158 (market cap $73.92B). The key difference: Target Corporation is far larger — about 5.2× Revvity Inc's market cap, and Target Corporation pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| RVTY | TGT | |
|---|---|---|
Market Cap | $14.18B | $73.92B |
Sector | Technology | Consumer Cyclical |
52-Week High | $130.94 | $169.90 |
52-Week Low | $82.26 | $83.68 |
Enterprise Value | $16.50B | $87.20B |
Dividend Yield | 0.22% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Target Corporation (TGT) trades at $162.71, down 1.05% on the day, with strong technical momentum and solid fundamentals. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue remains stable around $107 billion with improving profitability margins. Recent news highlights CEO Michael Fiddelke's successful turnaround strategy and the company's expanding non-merchandise revenue streams.
Target presents a balanced investment case with fair valuation metrics and strong dividend history, though competitive retail pressures and valuation expansion pose risks. Analyst consensus leans slightly bullish with a $166.67 price target, representing modest upside potential from current levels. The company's operational efficiency improvements and digital growth initiatives support continued earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
